1.Johannessen Landmark, C, Larsson, PG, Rytter, E, Johannessen, SI. Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions. Epilepsy Res. 2009; 87(1): 31–39.
2.Hayes, J, Prah, P, Nazareth, I, etal. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS One. 2011; 6(12): e28725.
3.Barbui, C, Conti, V, Purgato, M, etal. Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. Epidemiol Psychiatr Sci. 2013; 22(4): 355–361.
4.Adedinsewo, DA, Thurman, DJ, Luo, YH, etal. Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Res A Clin Mol Teratol. 2013; 97(6): 403–408.
5.Gentile, S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord. 2006; 8(3): 207–220.
6.Gentile, S. Bipolar disorder and pregnancy: to treat or not to treat? BMJ. 2012; 345: e7367.
7.Vajda, FJ, O'Brien, TJ, Graham, JE, Lander, CM, Eadie, MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013; 81(11): 999–1003.
8.Meador, KJ. Comment: valproate dose effects differ across congenital malformations. Neurology. 2013; 81(11): 1002.
9.Pennell, PB, Klein, AM, Browning, N, etal. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449–456.
10.FDA Drug Safety Communication. Valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. http://www.fda.gov/Drugs/DrugSafety/ucm350684.htm. Accessed: July 5, 2013.
11.Koch, S, Titze, K, Zimmermann, RB, etal. Long-term epilepsy and neuropsychological consequences of maternal anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia. 1999; 40(9): 1237–1243.
13.Steinhausen, HC, Losche, G, Koch, S, Helge, H. The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatr. 1994; 83(9): 955–960.
14.Losche, G, Steinhausen, HC, Koch, S, Helge, H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr. 1994; 83(9): 961–966.
15.Koch, S, Jäger-Roman, E, Lösche, G, etal. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr. 1996; 84(6): 739–746.
16.Adab, N, Jacoby, D, Smith, D, Chadwick, D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001; 70(1): 15–21.
17.Dean, CS, Hailey, H, Moore, SJ, etal. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet. 2002; 39(4): 251–259.
18.Gaily, E, Kantola-Sorsa, E, Hiilesmaa, V, etal. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004; 362(1): 28–32.
19.Eriksson, K, Viinikainen, K, Monkkonen, A, etal. Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005; 65(3): 189–200.
20.Viinikainen, K, Eriksson, K, Monkkonen, A, etal. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006; 9(4): 636–640.
21.Thomas, SV, Ajaykumar, B, Sindhu, K, etal. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008; 13(1): 229–236.
22.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009; 360(16): 1597–1605.
23.McVearry, KM, Gaillard, WD, VanMeter, J, Meador, KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav. 2009; 16(4): 609–616.
24.Cohen, MJ, Meador, KJ, Browning, N, etal. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral/functioning at age 3 years. Epilepsy Behav. 2011; 22(2): 240–246.
25.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology. 2012; 78(16): 1207–1214.
26.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013; 12(3): 244–252.
27.Cohen, MJ, Meador, KJ, Browning, N, etal, for the NEAD study group. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav. 2013; 29(2): 308–315.
28.Meador, KJ, Baker, GA, Browning, N, etal, for the NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011; 134(Pt 2): 396–404.
29.Adab, N, Kini, U, Vinten, J, etal. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004; 75(11): 1575–1583.
30.Vinten, J, Adab, N, Kini, U, etal, for the Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology. 2005; 64(6): 949–954.
31.Vinten, J, Bromley, RL, Taylor, J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav. 2009; 14(1): 197–201.
32.Bromley, RL, Mawer, G, Love, J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010; 51(10): 2058–2065.
33.Shallcross, R, Bromley, RL, Irwin, B, etal, on behalf of the Liverpool/Manchester Neurodevelopment Group and the UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4): 383–389.
34.Bromley, RL, Mawer, G, Clayton-Smith, J, Baker, GA, on behalf of the Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008; 71(28): 1923–1924.
35.Bromley, RL, Mawer, GE, Briggs, M, etal, on Behalf of the Liverpool and Manchester Neurodevelopment Group.. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013; 84(6): 637–643.
36.Johnson, CP, Myers, SM. American Academy of Pediatrics Council on Children with Disabilities. Identification and evaluation of children with autistic spectrum disorders. Pediatrics. 2007; 120(5): 1183–1215.
37.Nadebaum, C, Anderson, V, Vajda, F, etal. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc. 2011; 17(1): 133–142.
38.Nadebaum, C, Anderson, V, Vajda, F, etal. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology. 2011; 76(8): 719–726.
39.Cummings, C, Stewart, M, Stevenson, M, Morrow, J, Nelson, J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011; 96(7): 643–647.
40.Kantola-Sorsa, E, Gaily, E, Isoaho, M, Korkman, M. Neuropsychological outcomes in children of mothers with epilepsy. J Int Neuropsychol Soc. 2007; 13(4): 642–652.
41.Christensen, J, Grønborg, TK, Sørensen, MJ, etal. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 309(16): 1696–1703.
42.Veiby, G, Daltvei, AK, Schjølberg, S, etal. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013; 54(8): 1462–1472.
43.Rosner, B. Fundamentals of Biostatistics. Belmont, CA: Duxbury-Brooks/Cole; 2006.
44.Veiby, G, Engelsen, BA, Gilhus, NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013; 70(11): 1367–1374.
45.Thomas, JM, Benham, AL, Gean, M, etal. Practice parameters for the psychiatric assessment of infant and toddlers (0-36 months). American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997; 36(10 Suppl): S21–S36.
46.Meisels, SJ, Provence, S. Screening and Assessment: Guidelines for Identifying Young Disabled and Developmentally Vulnerable Children and Their Families. Washington, DC: Zero to Three/National Center for Clinical Infants Program; 1989.
47.Gentile, S. SSRIs in pregnancy and lactation with emphasis on neurodevelopmental outcome. CNS Drugs. 2005; 19(7): 623–633.
48.Thapar, A, Fowler, T, Rice, F, etal. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003; 160(11): 1985–1989.
49.Larsson, HJ, Eaton, WW, Madsen, KK. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005; 161(10): 916–925.
50.Hultman, CM, Sparén, P, Cnattingius, S. Perinatal risk factors for infantile autism. Epidemiology. 2002; 13(4): 417–423.
51.Easterbrook, PJ, Berlin, JA, Gopalan, R, Matthews, DR. Publication bias in clinical research. Lancet. 1991; 337(8746): 867–872.
52.Wright, TL, Hoffman, LH, Davies, . Lithium teratogenicity. Lancet. 1970; 24; 2(7678): 876.
53.Pennell, PB, Klein, AM, Browning, N, etal, for the NEAD Study Group. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449–456.
54.Fox, AW, Diamond, ML, Spiering, EL. Migraine during pregnancy: options for therapy. CNS Drugs. 2005; 19(6): 465–481.
56.Holmes, LB, Hernandez-Diaz, S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012; 94(8): 599–606.
58.Campbell, E, Kennedy, F, Irwin, B, etal. Malformation risks of antiepileptic drug monotherapies in pregnancy. J Neurol Neurosurg Psychiatry. 2013; Nov; 84(11): e2.
59.Gentile, S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Exp Opin Drug Saf. 2012; 11(3): 425–437.
60.Vajda, FJ, Graham, J, Roten, A, etal. Teratogenicity of the newer antiepileptic drugs—the Australian experience. J Clin Neurosci. 2012; 19(1): 57–59.
61.Gentile, S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophr Bull. 2010; 36(3): 518–544.
62.Kjaer, D, Christensen, J, Becha, BH, etal. Preschool behavioral problems in children prenatally exposed to antiepileptic drugs—a follow-up study. Epilepsy Behav. 2013; 29(2): 407–411.
63.Boden, R, Lundgren, M, Brandt, L, etal. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012; 345: e7085.
65.Frederick, IO, Qiu, C, Enquobahrie, DA, etal. Lifetime prevalence and correlates of migraine among women in a Pacific Northwest pregnancy cohort study. Headache. In press. doi: 10.1111/head.12206.
66.Wright, G, Patel, M. Focal migraine and pregnancy. BMJ. 1986; 293(6561): 1557–1558.
67.MacGregor, EA. Headache in pregnancy. Neurol Clin. 2012; 30(3): 835–866.